Piramal Pharma Limited
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, i… Read more
Piramal Pharma Limited (PPLPHARMA) - Total Assets
Latest total assets as of September 2025: ₹161.89 Billion INR
Based on the latest financial reports, Piramal Pharma Limited (PPLPHARMA) holds total assets worth ₹161.89 Billion INR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Piramal Pharma Limited - Total Assets Trend (2021–2025)
This chart illustrates how Piramal Pharma Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Piramal Pharma Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Piramal Pharma Limited's total assets of ₹161.89 Billion consist of 37.0% current assets and 63.0% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹0.00 | 3.2% |
| Accounts Receivable | ₹23.50 Billion | 15.0% |
| Inventory | ₹23.13 Billion | 14.8% |
| Property, Plant & Equipment | ₹0.00 | 0.0% |
| Intangible Assets | ₹29.39 Billion | 18.7% |
| Goodwill | ₹11.48 Billion | 7.3% |
Asset Composition Trend (2021–2025)
This chart illustrates how Piramal Pharma Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Piramal Pharma Limited's current assets represent 37.0% of total assets in 2025, an increase from 30.7% in 2021.
- Cash Position: Cash and equivalents constituted 3.2% of total assets in 2025, up from 2.6% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 25.0% of total assets, an increase from 20.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 18.7% of total assets.
Piramal Pharma Limited Competitors by Total Assets
Key competitors of Piramal Pharma Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Piramal Pharma Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Piramal Pharma Limited generates 0.58x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Piramal Pharma Limited generates $ 0.58 in net profit.
Piramal Pharma Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.43 | 1.03 | 1.29 |
| Quick Ratio | 0.77 | 0.56 | 0.97 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₹17.93 Billion | ₹ 1.44 Billion | ₹ 4.41 Billion |
Piramal Pharma Limited - Advanced Valuation Insights
This section examines the relationship between Piramal Pharma Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.55 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 2.4% |
| Total Assets | ₹156.78 Billion |
| Market Capitalization | $960.51 Million USD |
Valuation Analysis
Below Book Valuation: The market values Piramal Pharma Limited's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Piramal Pharma Limited's assets grew by 2.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Piramal Pharma Limited (2021–2025)
The table below shows the annual total assets of Piramal Pharma Limited from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | ₹156.78 Billion | +2.39% |
| 2024-03-31 | ₹153.12 Billion | +5.43% |
| 2023-03-31 | ₹145.23 Billion | +13.48% |
| 2022-03-31 | ₹127.97 Billion | +122.30% |
| 2021-03-31 | ₹57.57 Billion | -- |